Jiang Jiarui, Fan Mingjie, Yuan Weian, Yue Dawei, Wang Zhengtao, Yang Li, Huang Wendong, Jin Lihua, Wang Xu, Ding Lili
The MOE Key Laboratory for Standardization of Chinese Medicines, the SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese Medicines, and the Shanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
Shanghai R&D Center for Standardization of Traditional Chinese Medicines, Shanghai, People's Republic of China.
Am J Physiol Gastrointest Liver Physiol. 2025 Jun 1;328(6):G774-G790. doi: 10.1152/ajpgi.00387.2024. Epub 2025 May 8.
Farnesoid X receptor (FXR), predominantly expressed in the liver and intestine, plays a crucial role in regulating bile acid (BA) metabolism. However, the specific contributions of FXR in different tissues to BA homeostasis remain unclear. To elucidate the comprehensive roles of FXR, we developed a novel double tissue-specific knockout (KO) mouse model of in both liver and intestine (). Notably, mice exhibited significantly increased BA levels in the serum and liver, which were consistent with whole body KO mice (). However, mice only showed elevated hepatic BA concentration, whereas displayed remarkably increased BA concentration in feces. deletion increased the BA synthesis genes mRNA level, such as and , but reduced the expression of FXR downstream target genes and . These findings provide a valuable model to underscore the pivotal functions of tissue-specific FXR in maintaining BA homeostasis. Moreover, these insights facilitate the development of FXR-targeted therapeutic strategies for the BA dysregulation disease treatment. We successfully developed a double tissue-specific knockout (DKO) mouse model, which provides a novel tool for investigation of FXR functions in the liver and intestine. Unlike whole body KO, the DKO model excludes the FXR impact on other tissues. mice exhibited significantly increased BA levels in the serum and liver, which were consistent with mice. We established a powerful tool for therapeutic strategies for bile acid metabolism disorders associated with FXR.